Do online doctors check PMP for Strattera?

If you’ve been struggling with ADHD symptoms—difficulty focusing at work, trouble organizing your day, or feeling constantly restless—you’re not alone. Adult ADHD affects millions of Americans, and finding effective treatment can feel overwhelming, especially when juggling busy schedules or limited access to specialists.

The good news? Telehealth has transformed how people access ADHD care, including medications like Strattera (atomoxetine), a non-stimulant option that can be prescribed entirely through virtual appointments. But navigating the rules around telehealth prescribing—especially for ADHD medications—can be confusing. Federal and state regulations are constantly evolving, and understanding what’s legal, safe, and right for you matters more than ever.

In this comprehensive guide, we’ll walk you through everything you need to know about getting ADHD non-stimulant medication via telehealth in 2025, including current laws, state-by-state differences, what to expect from your virtual visit, and how services like Klarity Health make accessing care simpler and more transparent.

Understanding ADHD Non-Stimulant Medications

What Is Strattera and How Does It Work?

Strattera (atomoxetine) is an FDA-approved medication for treating ADHD in children (ages 6+) and adults. Unlike stimulant medications such as Adderall or Ritalin, Strattera is not a controlled substance—a crucial distinction that affects how it can be prescribed via telehealth.

Strattera works by selectively inhibiting the reuptake of norepinephrine, a brain chemical that plays a key role in attention and impulse control. While stimulants work almost immediately, Strattera typically takes 4–6 weeks to reach full effectiveness, making it a longer-term management option rather than a quick fix.

Why Choose a Non-Stimulant for ADHD?

Non-stimulant medications like Strattera offer several advantages for certain patients:

• No abuse potential: Because Strattera isn’t a controlled substance, there’s no risk of dependency or misuse
• Smoother symptom control: Effects last throughout the day without the ‘peaks and valleys’ some people experience with stimulants
• Fewer cardiovascular effects: May be safer for patients with certain heart conditions or high blood pressure
• No controlled substance restrictions: Easier to prescribe, refill, and manage—especially via telehealth
• Good for co-occurring conditions: Often effective for people with ADHD plus anxiety or substance use history

That said, Strattera isn’t right for everyone. Common side effects include decreased appetite, nausea, fatigue, and mood changes. The FDA also requires a warning about potential suicidal thoughts in children and adolescents, though this risk is rare. Your provider will discuss whether Strattera or another option best fits your needs.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Legal Landscape: Can You Actually Get ADHD Meds Via Telehealth?

Federal Rules: Where Things Stand in Late 2025

Here’s the straightforward answer: Yes, you can legally receive ADHD non-stimulant medication like Strattera through telehealth in all 50 states, as long as your provider is licensed in your state and follows standard medical practices.

For non-controlled medications, there has never been a federal restriction on telehealth prescribing. The Ryan Haight Act—a 2008 federal law designed to prevent illegal online pharmacies—only requires an in-person medical exam before prescribing controlled substances (like stimulant ADHD medications). Since Strattera isn’t controlled, this federal requirement doesn’t apply.

However, the landscape gets more complex if you’re considering stimulant medications. The DEA’s COVID-era telehealth flexibilities currently allow providers to prescribe Schedule II-V controlled substances (including Adderall, Vyvanse, and Ritalin) via telehealth without a prior in-person exam. These temporary rules have been extended through December 31, 2025, with a potential fourth extension anticipated for 2026.

What this means for patients: If you only need Strattera or another non-stimulant, federal law poses no barriers to telehealth treatment. If you’re considering stimulant options, you can currently access them via telehealth, but stay informed about potential rule changes in 2026.

State-by-State Variations: What You Need to Know

While federal law sets a baseline, individual states have their own telehealth regulations. Most states now fully support telehealth for ADHD treatment, but a few have implemented additional requirements:

Most Telehealth-Friendly States:

• California, Illinois, Pennsylvania: No in-person visit requirements for telehealth ADHD treatment; comprehensive telehealth parity laws in place
• New Hampshire: Recently removed prior in-person requirements (as of August 2025), now only requiring annual follow-up evaluations for controlled medication prescriptions
• Georgia: No state-mandated in-person exam for telehealth prescribing; follows federal guidelines

States with Additional Requirements:

• New York: Implemented strict rules in May 2025 requiring an initial in-person evaluation before prescribing any controlled substance via telehealth (doesn’t affect non-controlled Strattera prescriptions)
• Alabama: Requires an in-person visit within 12 months for ongoing telehealth treatment, though mental health services are exempt from this rule
• Florida: Generally prohibits telehealth prescribing of Schedule II stimulants unless treating a psychiatric condition (ADHD qualifies as psychiatric, so stimulants are permitted; Strattera has no restrictions)
• Texas: Very telehealth-friendly for mental health; main restriction is that nurse practitioners cannot prescribe Schedule II stimulants in outpatient settings (physicians can)

For non-stimulant medications like Strattera, virtually no state requires an in-person visit as a prerequisite to telehealth prescribing. The provider must simply meet the same standard of care they would for an in-person patient—conducting a thorough evaluation, confirming diagnosis, and ensuring the medication is appropriate.

How Telehealth ADHD Evaluations Actually Work

What to Expect from Your Virtual Visit

Getting an ADHD diagnosis and prescription via telehealth isn’t a rubber-stamp process. Legitimate providers follow rigorous evaluation protocols to ensure accurate diagnosis and safe treatment:

Initial Consultation (45-60 minutes):

• Comprehensive symptom review using DSM-5 diagnostic criteria
• Discussion of symptoms across multiple settings (work, home, relationships)
• Review of childhood history (ADHD symptoms must have been present before age 12)
• Assessment of other mental health conditions (depression, anxiety, substance use)
• Medical history review to identify contraindications
• Discussion of treatment options, including therapy, lifestyle changes, and medications

Diagnostic Tools:

• Standardized rating scales (like the Adult ADHD Self-Report Scale)
• Collateral information from family members or partners when possible
• Review of past evaluations, school records, or previous medication trials
• Questions about daily functioning and impact on quality of life

Treatment Planning:

• Discussion of medication options (stimulant vs. non-stimulant)
• Review of potential side effects and monitoring requirements
• Setting realistic expectations for symptom improvement
• Coordinating with therapy or coaching services
• Establishing a follow-up schedule

Reputable telehealth providers like Klarity Health ensure every patient receives this thorough evaluation, not just a quick questionnaire. The goal is accurate diagnosis and personalized treatment—the same standard you’d expect from an in-person specialist.

Documentation and Identity Verification

Because ADHD medications (especially stimulants) have been subject to misuse, telehealth providers implement strict verification processes:

• Photo ID verification: To confirm you are who you say you are
• State residency confirmation: Providers must be licensed in your state
• Medical records release: You may be asked to share past evaluations or medication history
• Pharmacy verification: Ensuring your prescription goes to a legitimate pharmacy
• Prescription Drug Monitoring Program (PDMP) checks: While not legally required for Strattera, many providers review your controlled substance history as part of comprehensive care

These safeguards protect both patients and providers, ensuring treatment is appropriate and reducing the risk of diversion or misuse.

Who Can Prescribe ADHD Medications via Telehealth?

Understanding Provider Types and Authority

Not all telehealth providers have the same prescribing authority, especially when it comes to controlled substances:

Physicians (MD/DO):In all 50 states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, assuming they hold appropriate state licensure and DEA registration (for controlled substances).

Nurse Practitioners (NPs):NP prescribing authority varies significantly by state:

• Full Practice Authority States (New York, Illinois, New Hampshire, California after experience requirements): NPs can independently prescribe Schedule II-V medications including stimulants
• Collaborative Practice States (Florida, Pennsylvania): NPs require physician oversight but can prescribe controlled substances with proper delegation
• Restricted States (Georgia, some limitations in Texas): NPs cannot prescribe Schedule II stimulants or face significant restrictions

For non-controlled medications like Strattera, NPs in all states can prescribe under at least a collaborative agreement, if not independently.

Physician Assistants (PAs):Similar to NPs, PA authority depends on state law and supervising physician agreements. Most states allow PAs to prescribe controlled substances under appropriate supervision, though some (like Texas) restrict Schedule II prescribing to hospital or hospice settings.

Why This Matters: When choosing a telehealth service, verify what types of providers are available in your state. Services like Klarity Health match you with appropriately licensed and credentialed providers—whether an MD, DO, or NP—who can legally prescribe your medication.

Safety Considerations and Red Flags

What Legitimate Telehealth Looks Like

The telehealth ADHD space has faced scrutiny following investigations into companies like Cerebral and Done in 2022-2023 for allegedly over-prescribing stimulants with inadequate oversight. These cases led to DEA probes and ultimately caused some platforms to stop prescribing controlled substances entirely.

Signs of a reputable telehealth provider:

• Requires comprehensive video evaluation (not just a questionnaire)
• Uses licensed providers in your state
• Discusses non-medication options and combination treatment
• Implements regular follow-ups and medication monitoring
• Checks prescription drug monitoring programs
• Has clear policies against ‘guaranteed prescriptions’
• Coordinates care with your primary care provider when appropriate
• Provides transparent pricing and accepts insurance when possible

Red flags to avoid:

• Promises medications without proper evaluation
• Requires payment before diagnosis
• Doesn’t verify your identity or medical history
• Offers to ship medications from outside the U.S.
• Uses only text-based consultations for controlled substances
• Prescribes unusually high doses or early refills without justification
• Doesn’t discuss side effects or monitoring requirements

Patient Eligibility and Contraindications

Not everyone is a good candidate for telehealth ADHD treatment. You may be directed to in-person care if you have:

• Active substance use disorder or recent history of stimulant misuse
• Severe, uncontrolled cardiovascular disease
• Serious mental health conditions requiring in-person psychiatric care (active suicidal ideation, psychosis)
• Complex medical history requiring physical examination
• Age considerations (most telehealth platforms don’t treat young children; some require age 18+ for controlled medications)

For Strattera specifically, contraindications include:

• Narrow-angle glaucoma
• Use of MAO inhibitor antidepressants within the past 14 days
• Severe liver disease
• Serious heart problems or structural heart defects

Your telehealth provider will screen for these conditions during your evaluation and may recommend in-person assessment or alternative treatments if needed.

The Klarity Health Advantage: Transparent, Accessible ADHD Care

Navigating telehealth ADHD treatment doesn’t have to be complicated. Klarity Health offers a streamlined approach that addresses common pain points:

Provider Availability: Klarity’s network includes board-certified psychiatrists, psychiatric nurse practitioners, and other mental health professionals licensed across multiple states. Most patients can schedule an initial appointment within days, not months—crucial when ADHD symptoms are affecting your work, relationships, or daily functioning.

Transparent Pricing: No surprise bills or hidden fees. Klarity clearly outlines costs upfront, whether you’re using insurance or paying out-of-pocket. Cash-pay options provide flexibility for those with high-deductible plans or limited mental health coverage.

Insurance and Cash Pay Options: Klarity accepts many major insurance plans and also offers affordable self-pay rates. This dual approach means you can access care regardless of your insurance situation—especially important since many traditional ADHD specialists don’t accept insurance or have long waitlists.

Comprehensive Treatment Approach: Beyond prescriptions, Klarity providers discuss therapy referrals, lifestyle modifications, and combination treatments. If Strattera isn’t the right fit, your provider can explore alternatives—whether another non-stimulant, a stimulant option (when appropriate), or non-medication strategies.

Ongoing Support: ADHD treatment isn’t one-and-done. Klarity facilitates regular follow-ups to monitor medication effectiveness, adjust doses, and address any concerns. This continuity of care helps ensure you’re getting optimal symptom management over time.

Practical Considerations: What Happens After Your Prescription

Getting Your Medication Filled

Once your provider prescribes Strattera, they’ll send an electronic prescription to your pharmacy of choice. Because Strattera isn’t a controlled substance, the process is straightforward:

• Prescription delivery: E-prescriptions arrive at your pharmacy within minutes to hours
• Refills allowed: Strattera prescriptions can include refills (unlike Schedule II stimulants which require a new prescription each month)
• Supply duration: Providers can prescribe up to a 90-day supply, though they may start with 30 days to monitor initial tolerance
• Pharmacy acceptance: Most pharmacies readily fill telehealth prescriptions from licensed providers

For controlled substances, the process involves more oversight (monthly prescriptions, PDMP checks, no refills), but Strattera’s non-controlled status simplifies ongoing medication management.

Monitoring and Follow-Up

Starting any ADHD medication requires monitoring:

Initial Phase (First 4-6 weeks):

• Weekly or bi-weekly check-ins to assess side effects
• Gradual dose titration to find the optimal amount
• Monitoring for rare but serious side effects (liver problems, severe mood changes, suicidal thoughts)
• Assessment of blood pressure and heart rate

Maintenance Phase:

• Monthly or quarterly follow-ups once stable
• Ongoing symptom tracking (rating scales, functional measures)
• Adjustment of medication as needed
• Coordination with therapy or other treatments
• Annual comprehensive reviews

Klarity Health’s platform makes these check-ins easy—often via brief video calls or secure messaging—ensuring you’re not left to manage medication alone.

Cost Considerations

Telehealth ADHD treatment typically costs less than traditional in-person care:

Initial Evaluation: $150-$300 (cash pay); insurance copays varyFollow-Up Visits: $75-$150 (cash pay); typically shorter than initial consultsMedication Costs:

• Strattera (brand): $400-$500/month without insurance
• Atomoxetine (generic): $30-$100/month without insurance
• With insurance: Usually $10-$50 copay

Many patients find telehealth more affordable when factoring in time off work, transportation, and childcare costs associated with in-person appointments. Klarity’s transparent pricing helps you budget appropriately.

Common Myths and Misconceptions

Myth #1: ‘Telehealth ADHD Providers Hand Out Prescriptions Too Easily’

Reality: Legitimate telehealth providers follow the same rigorous diagnostic criteria as in-person clinicians. The comprehensive evaluations required for ADHD diagnosis—detailed symptom history, functional impairment assessment, ruling out other conditions—are all conducted via telehealth. In fact, many platforms have tightened their protocols following regulatory scrutiny, implementing additional safeguards beyond what some in-person providers use.

Myth #2: ‘Non-Stimulants Don’t Really Work for ADHD’

Reality: While stimulants are often first-line treatment, non-stimulants like Strattera can be highly effective, especially for patients who:

• Experience significant anxiety alongside ADHD
• Have a history of substance use concerns
• Don’t tolerate stimulant side effects (appetite suppression, sleep problems, increased heart rate)
• Prefer not to take a controlled substance
• Need consistent 24-hour symptom coverage

Clinical trials show that approximately 70% of patients respond well to Strattera, with symptom improvement comparable to stimulants for many people—just with a different side effect profile and slower onset.

Myth #3: ‘Pharmacies Won’t Fill Telehealth Prescriptions’

Reality: Pharmacies fill valid prescriptions from licensed providers, regardless of whether the visit was telehealth or in-person. E-prescriptions are now standard practice. While some pharmacies scrutinized certain telehealth stimulant prescriptions during the 2023 Cerebral/Done controversies, this rarely affects Strattera prescriptions. Using a reputable telehealth service and establishing a relationship with one pharmacy helps prevent any issues.

Myth #4: ‘You Don’t Need Follow-Up Care with Telehealth’

Reality: Ongoing monitoring is essential for safe, effective ADHD treatment—whether care is delivered in-person or via telehealth. Strattera requires several weeks to reach full effect and may need dose adjustments. Blood pressure monitoring, liver function tests (in some cases), and mental health check-ins are all important. Reputable telehealth providers schedule regular follow-ups and encourage patients to report any concerning symptoms promptly.

Looking Ahead: What to Expect in 2026 and Beyond

Potential Regulatory Changes

The telehealth landscape continues to evolve. Key developments to watch:

DEA Rulemaking: The current temporary rule allowing telehealth prescribing of controlled substances expires December 31, 2025. While a fourth extension is anticipated, the DEA is also working on permanent regulations that may include:

• Special telemedicine registration requirements for providers
• Possible requirement for at least one in-person visit within a certain timeframe for stimulant prescriptions
• Enhanced guardrails to prevent misuse while preserving access

Congressional Action: Bills like the TREATS Act aim to codify telehealth flexibilities and expand cross-state licensure for mental health providers. While no major legislation has passed yet, momentum is building for permanent solutions.

State-Level Evolution: More states are moving toward flexible telehealth regulations. New Hampshire’s 2025 reforms (removing in-person requirements) exemplify this trend. Simultaneously, states are strengthening oversight through mandatory PDMP checks and e-prescribing requirements—balancing access with safety.

Impact on Non-Stimulant Prescribing

Because Strattera and other non-stimulants aren’t controlled substances, they’re largely insulated from DEA regulatory changes. Even if new rules require in-person visits for stimulant prescriptions, non-stimulant ADHD medications will likely remain fully accessible via telehealth.

This means that for patients who do well on Strattera or other non-controlled options (like Qelbree or guanfacine), telehealth access should remain stable regardless of regulatory shifts affecting stimulants.

Practical Tips for Telehealth ADHD Patients

Maximizing Your Virtual Care Experience

1. Prepare for Your Appointment:

• Compile a list of current and past medications
• Document your symptoms with specific examples (when, where, how they impact your life)
• Gather any previous ADHD evaluations or school records
• List questions or concerns you want to address
• Have your insurance card and pharmacy information ready

2. Be Honest and Thorough:

• Disclose any substance use history (providers aren’t there to judge—they need accurate information for safe prescribing)
• Mention all medical conditions and medications, including over-the-counter supplements
• Describe the real impact of symptoms (work performance, relationships, daily tasks)
• Share any previous medication experiences (what worked, what didn’t, side effects)

3. Follow Through on Treatment:

• Attend all scheduled follow-ups (don’t disappear after getting your prescription)
• Track your symptoms and side effects—many apps can help with this
• Take medication as prescribed (Strattera needs consistent daily dosing to work)
• Report concerns promptly rather than waiting for the next appointment
• Request refills in advance (don’t wait until you’re out of medication)

4. Coordinate Your Care:

• Inform your primary care provider about your ADHD treatment
• Share medication information with other specialists
• Consider combining medication with therapy, coaching, or support groups
• Use one pharmacy consistently to help them track your medications and catch potential interactions

5. Stay Informed:

• Monitor communications from your telehealth provider about policy changes
• Understand your state’s specific telehealth rules if you plan to move
• Keep copies of your prescriptions and medical records
• Know the plan for continued care if regulations change (backup options, local providers, etc.)

When to Consider Transitioning to In-Person Care

Telehealth is excellent for many patients, but some situations benefit from in-person evaluation:

• Complex diagnostic uncertainty (is it ADHD, or something else like thyroid issues, sleep apnea, or bipolar disorder?)
• Multiple co-occurring conditions requiring specialized psychiatric assessment
• Serious side effects needing physical examination
• Need for comprehensive neuropsychological testing
• Personal preference for face-to-face care
• Requirements from school or workplace for in-person evaluation

Quality telehealth providers will recognize when in-person care is more appropriate and help facilitate referrals.

Strattera vs. Stimulants: Making the Right Choice

Comparing Medication Options

Neither option is inherently ‘better’—the right choice depends on your individual symptoms, medical history, lifestyle, and preferences. Many patients try both types over time to find what works best.

When Strattera Might Be the Better Choice

Consider discussing Strattera with your provider if:

• You have a history of substance use or are in recovery
• You experience significant anxiety that might worsen with stimulants
• You’ve had problematic side effects from stimulants (severe appetite loss, insomnia, jitteriness)
• You prefer not to take a controlled substance
• You need consistent symptom coverage throughout the day and night
• You’re concerned about the stigma or logistics of monthly controlled substance prescriptions
• You have certain cardiovascular conditions that make stimulants riskier

Frequently Asked Questions

Is Strattera as effective as Adderall for ADHD?

Strattera and stimulants like Adderall work differently but can be equally effective for the right patient. Clinical trials show both have similar response rates (around 70%), though individual experiences vary. Stimulants typically work faster and may provide more noticeable symptom improvement initially, while Strattera offers smoother, longer-lasting effects once it reaches full therapeutic levels. The ‘best’ medication depends on your specific symptoms, side effect tolerance, and life circumstances.

How long does it take to get an ADHD diagnosis via telehealth?

With services like Klarity Health, many patients can schedule an initial evaluation within 3-7 days. The diagnostic appointment itself typically lasts 45-60 minutes. If ADHD is diagnosed, your provider can prescribe medication the same day (assuming no contraindications). However, reaching optimal symptom control may take several weeks to months, especially with Strattera, as you work with your provider to find the right dose.

Can I use telehealth if I’ve never been diagnosed with ADHD before?

Yes, many patients receive their first ADHD diagnosis through telehealth. Providers will conduct a comprehensive evaluation including your childhood history, current symptoms, and functional impact. They may request collateral information from family members and review any relevant past records. Telehealth can be an excellent option for adults who struggled with ADHD symptoms for years but never received a formal diagnosis.

What if my state requires an in-person visit for controlled substances?

For Strattera, this isn’t an issue since it’s not controlled. If you’re considering a stimulant medication and your state (like New York) requires an initial in-person exam, you have options: (1) see a local provider for the initial visit, then transfer care to telehealth for ongoing management; (2) stick with non-stimulant options via telehealth; or (3) use a hybrid model where your telehealth provider coordinates with a local physician. Many telehealth services can help facilitate these arrangements.

Will my insurance cover telehealth ADHD treatment?

Most insurance plans now cover telehealth mental health services at the same rate as in-person visits, thanks to pandemic-era policy changes that many states made permanent. Coverage varies by plan, so check with your insurer. Klarity Health accepts many major insurance plans and can verify your benefits before your appointment. If insurance doesn’t cover telehealth or you prefer not to use it, cash-pay rates are typically $150-$300 for initial evaluation and $75-$150 for follow-ups—often more affordable than in-person specialists when you factor in time and travel costs.

Can I get my prescription transferred from an in-person provider to telehealth?

Yes, if you’re already taking Strattera or another ADHD medication, you can often transfer your care to a telehealth provider. They’ll review your current treatment, confirm the diagnosis, and can continue prescribing if appropriate. This can be especially helpful if your current provider retires, you move to a new area, or you simply prefer the convenience of virtual appointments.

Taking the Next Step: Getting Started with Telehealth ADHD Care

If you’re struggling with ADHD symptoms and haven’t found the right treatment—or if you’re newly recognizing symptoms that have affected you for years—telehealth offers an accessible pathway to diagnosis and care.

Ready to explore your options? Here’s how to get started:

1. Choose a reputable provider: Look for services that use licensed clinicians, require comprehensive evaluations, and have transparent policies. Klarity Health connects you with board-certified providers who specialize in ADHD and can prescribe medication when appropriate.

2. Schedule your initial consultation: Most telehealth platforms let you book online within days. Prepare by gathering relevant medical history, listing your symptoms with specific examples, and writing down questions.

3. Complete your evaluation: Be thorough and honest during your video appointment. Your provider needs complete information to make an accurate diagnosis and recommend safe, effective treatment.

4. Follow your treatment plan: Whether you’re prescribed Strattera, another medication, or start with therapy and lifestyle changes, consistent follow-through is key to managing ADHD successfully.

5. Maintain ongoing communication: ADHD treatment often requires adjustments over time. Stay connected with your provider through scheduled follow-ups and reach out with concerns as they arise.

Living with undiagnosed or undertreated ADHD doesn’t have to be your reality. With modern telehealth services, evidence-based treatment is more accessible than ever—combining the convenience of virtual care with the expertise of specialized providers.

At Klarity Health, we believe everyone deserves access to quality mental health care, regardless of location, schedule, or insurance status. Our network of experienced providers is here to help you understand your symptoms, explore treatment options, and develop a plan that fits your life.

Don’t let ADHD symptoms hold you back. Take the first step toward better focus, organization, and quality of life. Schedule your confidential evaluation with Klarity Health today and discover how telehealth ADHD treatment can work for you—with transparent pricing, flexible scheduling, and providers who truly understand adult ADHD.

References and Further Reading

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Substances’ – Federal Register (November 2024). Available at: FierceHealthcare.com. Official rule summary confirming DEA policy through December 31, 2025.

2. Sheppard Mullin Healthcare Law Blog – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ (August 15, 2025). National Law Review. Comprehensive 50-state survey of telehealth regulations including Florida, New Hampshire, and Texas updates.

3. RxAgent Compliance Blog – ‘The Telehealth Compliance Trap: What Providers Need to Know’ (October 2025). RxAgent.co. Analysis of state-specific telehealth rules including Alabama and New York requirements, written by PharmD with statutory citations.

4. Medical News Today – ‘Is Strattera a Controlled Substance?’ (January 14, 2025). Medically reviewed article. Explains that Strattera (atomoxetine) is not a DEA-controlled substance and discusses implications for prescribing.

5. McDermott Will & Emery – ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026’ (December 2025). MWE Insights. Details fourth DEA extension in OMB review process, expected to continue telehealth flexibilities into 2026.

This article is for informational purposes only and does not constitute medical advice. ADHD diagnosis and treatment should be individualized based on comprehensive evaluation by a licensed healthcare provider. Regulations are current as of December 2025 but may change. Always verify current rules with your provider or state medical board.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment